Carrier scattering factor is one of the most important parameters for semiconductors. In this paper, we propose the mechanism and the application method to analyze the carrier scattering factor(s) by comparing the ratios of electrical conductivity σ(T)/σ(T0 = 300 K) vs. temperature T in the theoretical calculation and experimental results. It is demonstrated that σ(T)/σ(T0 = 300 K) is only related to the carrier scattering factor when the density of states effective mass, m*, is assumed to be constant in small temperature ranges. Therefore, the carrier scattering factor dependence of the ratios of σ(T)/σ(T0 = 300 K) can be used to pinpoint the carrier scattering mechanism. Taking Bi0.5Sb1.5Te2.7+xSe0.3 as an example, it is found that no matter what theoretical models for the Seebeck coefficient over a range of the reduced Fermi energy are used, the analysis results for the scattering mechanism are unique. The reason behind such an observation is that the ratio of σ(T)/σ(T0) is only dependent on the carrier scattering for a certain material. As such, we can neglect the effect of degeneracy on the carrier scattering mechanism, and select the simplest theoretical Seebeck coefficient model to estimate the scattering mechanism before the self-consistent η(T) (reduced Fermi level) is obtained. The effect of temperature dependence of the m*(T) on the σ(T)/σ(T0) is also discussed.
11 July 2022 in ACS Applied Materials & Interfaces
Despite the side effects, chemotherapy is one of the most common treatments in colorectal cancer (CRC). An open-ended question about CRC chemotherapy, which has been discussed quite often, is with respect to the validation of prognostic or predictive factors. It is believed that personalized chemotherapy can improve the treatment outcome of patients with colorectal tumors. Though, Smurf1 is highly expressed in multiple tumors and plays a critical role in the occurrence and development of multiple cancers, it's role in the susceptibility of CRC response to chemotherapy is still unknown, Therefore, the study aimed to understand the role of Smurf1 in the susceptibility of CRC response to chemotherapy. The study showed that the knockdown of Smurf1 increases gemcitabine and cisplatin-induced HCT116 cells apoptosis in vitro. Furthermore, in vivo experiments showed that tumors that had low Smurf1 expression exhibited enhanced gemcitabine, cisplatin, and gemcitabine plus cisplatin anti-tumor effects in HCT116 cell-derived xenograft (CDX) models and patient-derived xenograft (PDX) models. In conclusion, the results indicated that Smurf1 inhibits the chemosensitivity of CRC to gemcitabine, cisplatin, and gemcitabine plus cisplatin. Therefore, downregulati1ng the Smurf1 expression is a potential strategy to increase the efficacy of gemcitabine and cisplatin in CRC patients.